Trends in hip fracture epidemiology in Australia: Possible impact of bisphosphonates and hormone replacement therapy

被引:63
作者
Fisher, A. A. [1 ,2 ]
O'Brien, E. D. [1 ]
Davis, M. W. [1 ,2 ]
机构
[1] Canberra Hosp, Dept Geriatr Med, Woden, ACT 2606, Australia
[2] Australian Natl Univ, Sch Med, Canberra, ACT, Australia
关键词
Hip fracture; Epidemiology; Bisphosphonates; Hormone replacement therapy; AGE-ADJUSTED INCIDENCE; ESTROGEN PLUS PROGESTIN; NEW-SOUTH-WALES; OSTEOPOROSIS TREATMENT; OLDER PATIENTS; UNITED-STATES; INTERVENTION THRESHOLDS; HOSPITAL ADMISSIONS; INCIDENCE RATES; LIFETIME RISK;
D O I
10.1016/j.bone.2009.04.244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purposes of this study were to analyse trends in hip fracture (HF) epidemiology over a 13-year period (1994-2007) in the Australian Capital Territory (ACT), to assess the potential impact of concurrent changes in hormone replacement therapy (HRT) and bisphosphonate use and to present a new prediction of HFs in Australia up to 2021. Annual sex- and age-specific incidence rates (per 100,000 population) were determined and standardized using the Australian 2006 population. The projected number of HFs was estimated by two models applying age- and sex-specific HF rates averaged for 2002-2006 (model I) or continuously changing as observed in this period (model 2, Poisson regression) to the projected population. In 2006 compared to 2001, the population :60 years in the ACT increased by 19.7%. Over the last 5 years the average annual incidence HF rate compared to the previous 3-year period decreased in females >= 60 years of age by 28.3%. Between 2001 and 2006 the number of prescriptions for HRT dispensed in the ACT declined by 54.6, while the number of prescriptions for bisphosphonate increased by 245%, accompanied by a decline in standardized incidence of HF rates of 36.4%, mainly in women (42.1%). This represents an annual cost for bisphosphonates per one prevented HF, of $A45,250 or $A576 person/year. Compared to 2006 the total number of HFs in Australia according to model I will increase in 2011 by 20.1% and in 2021 by 58.8%, but according to model 2 will decrease by 15.5% in 2011 and 27.5% in 2021. Our data suggest that the previously predicted rising trend in HFs in elderly women reversed, but did not so for men. This was coincident with a significant fall in HRT use and increased prescribing of bisphosphonates, which is cost-effective. However caution should be used in attributing causation as this is an ecological study. If trends in HF observed in 2002-2006 continue, the absolute number of HFs in Australia in 2011-2021 will stabilise or decline (which is more likely), despite the rapid ageing of the population. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:246 / 253
页数:8
相关论文
共 93 条
[81]   Health burden of hip and other fractures in Australia beyond 2000 - Projections based on the Geelong Osteoporosis Study [J].
Sanders, KM ;
Nicholson, GC ;
Ugoni, AM ;
Pasco, JA ;
Seeman, E ;
Kotowicz, MA .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (10) :467-470
[82]   International variation in the incidence of hip fractures:: Cross-national project on osteoporosis for the World Health Organization program for research on aging [J].
Schwartz, AV ;
Kelsey, JL ;
Maggi, S ;
Tuttleman, M ;
Ho, SC ;
Jónsson, PV ;
Poór, G ;
de Castro, JAS ;
Xu, L ;
Matkin, CC ;
Nelson, LM ;
Heyse, SP .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (03) :242-253
[83]  
Stephenson Shaun, 2003, N Z Med J, V116, pU665
[84]   Hormone replacement therapy and prevention of nonvertebral fractures - A meta-analysis of randomized trials [J].
Torgerson, DJ ;
Bell-Syer, SEM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2891-2897
[85]   Cost-effective osteoporosis treatment thresholds: the United States perspective [J].
Tosteson, A. N. A. ;
Melton, L. J., III ;
Dawson-Hughes, B. ;
Baim, S. ;
Favus, M. J. ;
Khosla, S. ;
Lindsay, R. L. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :437-447
[86]   Survival and potential years of life lost after hip fracture in men and age-matched women [J].
Trombetti, A ;
Herrmann, F ;
Hoffmeyer, P ;
Schurch, MA ;
Bonjour, JP ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (09) :731-737
[87]   Efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture:: A randomized, controlled trial [J].
Vidán, M ;
Serra, JA ;
Moreno, C ;
Riquelme, G ;
Ortiz, J .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (09) :1476-1482
[88]   Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 [J].
Watson, Joanna ;
Wise, Lesley ;
Green, Jane .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (09) :843-849
[89]  
Watts Nelson B, 2004, J Manag Care Pharm, V10, P142
[90]   Gender differences in mortality after hip fracture: The role of infection [J].
Wehren, LE ;
Hawkes, WG ;
Orwig, DL ;
Hebel, JR ;
Zimmerman, SI ;
Magaziner, J .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (12) :2231-2237